Twist Bioscience to Report Fiscal 2021 First Quarter Financial Results on Thursday, February 4, 2020
Twist Bioscience (NASDAQ: TWST) will announce its fiscal 2021 first-quarter financial results on February 4, 2020, after market close. A conference call for analysts and investors will take place at 4:30 p.m. ET to discuss these results. Twist Bioscience specializes in high-quality synthetic DNA production using its innovative silicon platform, catering to multiple industries including healthcare and agriculture. The company is focused on expanding its DNA synthesis capabilities and exploring opportunities in digital data storage and biologics.
- Innovative manufacturing method for synthetic DNA on silicon chips.
- Broad range of synthetic DNA-based products for various industries.
- None.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2021 first quarter ended December 31, 2020, following the close of market on Thursday, February 4, 2020. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.
The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 7958297. A telephonic replay of the conference call will be available beginning approximately four hours after the call through February 11, 2021 and may be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay conference ID is 7958297. The webcast replay will be available for two weeks.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005301/en/
FAQ
What date will Twist Bioscience release its financial results for Q1 2021?
What is the conference call ID for the Twist Bioscience February 2020 financial results call?
What industries does Twist Bioscience serve with its synthetic DNA products?
